JP2013510853A - Ｃ型肝炎ウイルス阻害剤 - Google Patents

Ｃ型肝炎ウイルス阻害剤 Download PDF

Info

Publication number
JP2013510853A
JP2013510853A JP2012538863A JP2012538863A JP2013510853A JP 2013510853 A JP2013510853 A JP 2013510853A JP 2012538863 A JP2012538863 A JP 2012538863A JP 2012538863 A JP2012538863 A JP 2012538863A JP 2013510853 A JP2013510853 A JP 2013510853A
Authority
JP
Japan
Prior art keywords
methyl
imidazol
amino
azabicyclo
carbamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012538863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510853A5 (enExample
Inventor
リコ・ラヴォワ
ジョン・エイ・ベンダー
ヤン・ゾン
マコネン・ベレマ
オマール・ディ・ロペス
チェン・キ
ガン・ワン
ピヤセナ・ヘワワサム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43466793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013510853(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2013510853A publication Critical patent/JP2013510853A/ja
Publication of JP2013510853A5 publication Critical patent/JP2013510853A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
JP2012538863A 2009-11-11 2010-11-05 Ｃ型肝炎ウイルス阻害剤 Pending JP2013510853A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26011509P 2009-11-11 2009-11-11
US61/260,115 2009-11-11
US37880610P 2010-08-31 2010-08-31
US61/378,806 2010-08-31
PCT/US2010/055565 WO2011059887A1 (en) 2009-11-11 2010-11-05 Hepatitis c virus inhibitors

Publications (2)

Publication Number Publication Date
JP2013510853A true JP2013510853A (ja) 2013-03-28
JP2013510853A5 JP2013510853A5 (enExample) 2013-11-28

Family

ID=43466793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012538863A Pending JP2013510853A (ja) 2009-11-11 2010-11-05 Ｃ型肝炎ウイルス阻害剤

Country Status (21)

Country Link
US (6) US20110274648A1 (enExample)
EP (1) EP2499127B1 (enExample)
JP (1) JP2013510853A (enExample)
KR (1) KR20130036173A (enExample)
CN (1) CN102712623B (enExample)
AR (1) AR078976A1 (enExample)
AU (1) AU2010319801A1 (enExample)
BR (1) BR112012011100A2 (enExample)
CA (1) CA2780812A1 (enExample)
CL (1) CL2012001230A1 (enExample)
EA (1) EA201270622A1 (enExample)
ES (1) ES2690660T3 (enExample)
IL (1) IL219516A (enExample)
MA (1) MA33731B1 (enExample)
MX (1) MX2012005190A (enExample)
NZ (1) NZ600505A (enExample)
PE (1) PE20121354A1 (enExample)
PH (1) PH12012500922A1 (enExample)
TN (1) TN2012000214A1 (enExample)
TW (1) TWI475019B (enExample)
WO (1) WO2011059887A1 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024853B1 (ru) 2008-12-03 2016-10-31 Пресидио Фармасьютикалс, Инк. Ингибиторы ns5a вгс
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2758484A1 (en) * 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
ES2758726T3 (es) 2009-05-13 2020-05-06 Gilead Pharmasset Llc Compuestos antivirales
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
PL2628481T3 (pl) 2009-06-11 2016-08-31 Abbvie Bahamas Ltd Tripodstawione heterocykle jako inhibitory replikacji wirusa HCV zapalenia wątroby typu C
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8653070B2 (en) * 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091417A1 (en) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011119858A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119853A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
CA2804304C (en) * 2010-05-24 2020-02-25 Intellikine, Llc Heterocyclic compounds and uses thereof
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EA201591390A1 (ru) 2010-06-24 2016-06-30 Джилид Сайэнс, Инк. Пиразол[1,5-a]пиримидины для противовирусного лечения
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2012021704A1 (en) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8552047B2 (en) * 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
PT2729448E (pt) 2011-07-06 2015-12-02 Gilead Sciences Inc Compostos para o tratamento de vih
BR112014000563A2 (pt) 2011-07-09 2019-12-10 Sunshine Lake Pharma Co., Ltd composto, composição farmacêutica, e, uso do composto
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
AU2012332358B2 (en) 2011-11-03 2017-07-13 Theravance Biopharma R&D Ip, Llc Rod -like hepatitis C virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1H - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine
EP2794611B1 (en) 2011-12-22 2017-10-11 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013118097A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
HRP20191754T1 (hr) 2012-04-17 2020-01-24 Gilead Sciences, Inc. Spojevi i postupci za antivirusno liječenje
LT2850075T (lt) 2012-04-25 2017-05-10 Theravance Biopharma R&D Ip, Llc Piperazino-piperidino junginiai, kaip hepatito c viruso inhibitoriai
JP6006008B2 (ja) * 2012-06-14 2016-10-12 ユー・ディー・シー アイルランド リミテッド 化合物、有機電界発光素子並びに該有機電界発光素子を用いた発光装置、表示装置及び照明装置
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
WO2014082379A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co.,Ltd. Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention
WO2014082380A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015110048A1 (en) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
US10517870B2 (en) * 2015-07-30 2019-12-31 Bristol-Myers Squibb Company Aryl substituted bicycle heteroaryl compounds
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
PT3347352T (pt) 2016-08-19 2019-09-24 Gilead Sciences Inc Compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infeção pelo vírus hiv
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CA3089590C (en) 2018-02-15 2022-12-06 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102587504B1 (ko) 2018-02-16 2023-10-11 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
AU2019307500B2 (en) 2018-07-16 2022-09-29 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
TWI854067B (zh) 2019-11-26 2024-09-01 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
KR20230027275A (ko) 2020-06-25 2023-02-27 길리애드 사이언시즈, 인코포레이티드 Hiv 치료용 캡시드 저해제
JP7725617B2 (ja) 2021-05-21 2025-08-19 ギリアード サイエンシーズ， インコーポレイテッド ジカウイルス阻害剤としての五環式誘導体
WO2022246072A1 (en) 2021-05-21 2022-11-24 Gilead Sciences, Inc. Tetracyclic compounds for the treatment of zika virus infection
CA3238270A1 (en) 2021-12-03 2023-06-08 Gediminas J. Brizgys Therapeutic compounds for hiv virus infection
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
LT4440702T (lt) 2021-12-03 2025-08-25 Gilead Sciences, Inc. Terapiniai junginiai, skirti živ viruso infekcijai gydyti

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068140A1 (de) * 2007-11-30 2009-06-04 Stechert Stahlrohrmöbel GmbH Klappstuhl
WO2010065674A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010065668A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010132601A1 (en) * 2009-05-13 2010-11-18 Gilead Sciences, Inc. Antiviral compounds
WO2011054834A1 (en) * 2009-11-04 2011-05-12 Tibotec Pharmaceuticals Benzimidazole-imidazole derivatives

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
EP0679153A4 (en) 1993-01-14 1996-05-15 Magainin Pharma FINALLY MODIFIED AMINO ACIDS AND PEPTIDES.
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004005264A2 (en) 2002-07-05 2004-01-15 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
ES2348332T3 (es) 2005-09-16 2010-12-02 Arrow Therapeutics Limited Derivados de bifenilo y su uso en el tratamiento de la hepatitis c.
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
NZ569817A (en) 2005-12-21 2011-10-28 Abbott Lab Anti-viral compounds
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
CA2653924A1 (en) 2006-05-30 2007-12-06 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
US9873667B2 (en) 2006-07-27 2018-01-23 Emisphere Technologies Inc. Arylsulfanyl compounds and compositions for delivering active agents
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200831084A (en) 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
BRPI0907733A2 (pt) 2008-02-12 2015-07-14 Bristol Myers Squibb Co Inibidores do vírus da hepatite c
EP2250163B1 (en) 2008-02-12 2012-03-28 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2010008863A (es) 2008-02-13 2010-09-07 Bristol Myers Squibb Co Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatisis c.
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
EP2393359A4 (en) * 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
UY32462A (es) 2009-02-23 2010-09-30 Arrow Therapeutics Ltd Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CA2753313A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
RU2544010C2 (ru) * 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 ｃ형 간염 억제제
MX2011010084A (es) 2009-03-27 2011-10-14 Merck Sharp & Dohme Inhibidores de la replicacion del virus de la hepatitis c.
US8709999B2 (en) 2009-03-27 2014-04-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2758484A1 (en) 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
JP2012524761A (ja) 2009-04-24 2012-10-18 テイボテク・フアーマシユーチカルズ ジアリールエーテル類
CA2760205A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8772505B2 (en) 2009-05-29 2014-07-08 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2628481T3 (pl) 2009-06-11 2016-08-31 Abbvie Bahamas Ltd Tripodstawione heterocykle jako inhibitory replikacji wirusa HCV zapalenia wątroby typu C
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
RU2540897C2 (ru) 2009-08-07 2015-02-10 Тиботек Фармасьютикалз Производные бис-бензимидазола в качестве ингибиторов вируса гепатита с
WO2011015657A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
RU2012112824A (ru) 2009-09-03 2013-10-10 Тиботек Фармасьютикалз Производные бис-бензимидазола
SG178952A1 (en) 2009-09-04 2012-04-27 Glaxosmithkline Llc Chemical compounds
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8415482B2 (en) 2009-12-04 2013-04-09 National Health Research Institutes Proline derivatives
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
CA2784036A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
WO2011091417A1 (en) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011091532A1 (en) 2010-01-28 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2011119853A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2575866A4 (en) * 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068140A1 (de) * 2007-11-30 2009-06-04 Stechert Stahlrohrmöbel GmbH Klappstuhl
WO2010065674A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010065668A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010132601A1 (en) * 2009-05-13 2010-11-18 Gilead Sciences, Inc. Antiviral compounds
WO2011054834A1 (en) * 2009-11-04 2011-05-12 Tibotec Pharmaceuticals Benzimidazole-imidazole derivatives

Also Published As

Publication number Publication date
WO2011059887A1 (en) 2011-05-19
US20150322048A1 (en) 2015-11-12
MA33731B1 (fr) 2012-11-01
IL219516A (en) 2015-09-24
US20170355689A1 (en) 2017-12-14
AU2010319801A1 (en) 2012-06-28
US9303007B2 (en) 2016-04-05
CN102712623A (zh) 2012-10-03
US20130115193A1 (en) 2013-05-09
EP2499127A1 (en) 2012-09-19
KR20130036173A (ko) 2013-04-11
US20110274648A1 (en) 2011-11-10
TN2012000214A1 (en) 2013-12-12
ES2690660T3 (es) 2018-11-21
NZ600505A (en) 2013-12-20
US20150322031A1 (en) 2015-11-12
US20150197499A1 (en) 2015-07-16
PH12012500922A1 (en) 2012-11-26
PE20121354A1 (es) 2012-10-15
US9776981B2 (en) 2017-10-03
BR112012011100A2 (pt) 2019-09-24
CA2780812A1 (en) 2011-05-19
AR078976A1 (es) 2011-12-14
EA201270622A1 (ru) 2012-12-28
TWI475019B (zh) 2015-03-01
MX2012005190A (es) 2012-06-08
EP2499127B1 (en) 2018-09-05
IL219516A0 (en) 2012-06-28
TW201121955A (en) 2011-07-01
CL2012001230A1 (es) 2012-09-28
CN102712623B (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
JP5847284B2 (ja) Ｃ型肝炎ウイルス阻害剤
US9303007B2 (en) Hepatitis C virus inhibitors
JP5785189B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP5697679B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP5599792B2 (ja) Ｃ型肝炎ウイルス阻害剤としてのｂｉ−１ｈ−ベンズアミダゾール
JP5612661B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP5615352B2 (ja) Ｃ型肝炎ウイルス阻害剤
JP5596861B2 (ja) Ｃ型肝炎ウイルス阻害剤
MX2011009948A (es) Inhibidores del virus de la hepatitis c.
EP2435425A1 (en) Hepatitis c virus inhibitors
KR20110124774A (ko) Ｃ형 간염 바이러스 억제제
AU2010319764B2 (en) Hepatitis C virus inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131007

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303